Retatrutide Trial Sign Up: How Enrollment Works

You are not looking for another peptide sales page. You are trying to find the real retatrutide trial sign up path: where the study is listed, whether it is still recruiting, what the eligibility rules say, and who to contact if there is a site near you. That path is clinical research, not a shopping cart.

One thing said plainly. Retatrutide is investigational and not FDA-approved for any use. A clinical trial is a research study with a protocol, screening rules, site visits, and monitoring. Joining one does not guarantee that you receive retatrutide, because trials can assign people to different arms, including placebo.

Where to check retatrutide trial enrollment status

Start with two places: ClinicalTrials.gov and Lilly's own clinical trial finder. ClinicalTrials.gov is the public registry where study records list the sponsor, locations, recruiting status, eligibility criteria, study arms, and contact information. Lilly's trial finder points people toward company-sponsored studies and lets you search by condition and location.2

The main retatrutide obesity program is called TRIUMPH. On ClinicalTrials.gov, TRIUMPH-1 is listed as NCT05929066, a phase 3 study of retatrutide in adults with obesity or overweight who meet the study criteria.1 The status on a trial record can change, so check the listing itself rather than trusting a forum post or an old screenshot.

How clinical trial sign up actually works

Trial sign up usually starts online, but enrollment happens through a study team. You find the record, choose a nearby site if one exists, and contact the coordinator listed for that site. From there, the team may do a phone screen, ask for medical records, schedule a screening visit, and confirm whether you meet the protocol.

The protocol is the rulebook. It says who can join, what visits happen, what tests are required, how long the study lasts, what treatment arms exist, and what outcomes researchers measure. The FDA describes clinical trials as research studies designed to answer specific questions about safety and effectiveness, not normal treatment visits.3 ClinicalTrials.gov also explains that the public record is a study summary and that the study team handles the actual enrollment process.4

That is why a "sign up" button does not mean you are in. It means you have asked to be contacted or screened. The study may be full at your location. You may not meet a rule. You may need to travel. You may also decide the schedule is too demanding.

What TRIUMPH means for retatrutide

TRIUMPH is Lilly's phase 3 retatrutide program. The study records use the drug name retatrutide and the development code LY3437943. In the phase 2 obesity trial, retatrutide produced dose-related weight loss, with the highest-dose group losing up to 24.2% of body weight at 48 weeks.5 Phase 3 trials are designed to test the drug in larger groups and gather the evidence needed for regulatory review.

TRIUMPH-1 is one of the listings people find when they search for a retatrutide clinical trial sign up. Read the study record carefully. The study can have specific BMI criteria, health-history rules, medication restrictions, required visits, lab monitoring, and time commitments. It is not a general waitlist for future retail access.

Lilly has also reported phase 3 topline results from TRIUMPH-4, a study in people with obesity and knee osteoarthritis, with up to 71.2 pounds of average weight loss at 68 weeks in the 12 mg arm.6 That result is why search interest is high, but a headline result does not mean every trial site is open or that every person can enroll.

Eligibility: who may qualify for a retatrutide trial?

Eligibility depends on the exact study. A retatrutide trial may look for adults within a certain BMI range, with or without a weight-related condition, and may exclude people based on medical history, medications, recent use of other weight-loss drugs, pregnancy, certain endocrine conditions, or other safety rules. The listing is the starting point, but the study team makes the decision.

Think of eligibility in layers. First is the public checklist: age, BMI, condition, and location. Second is the screening conversation: medications, recent weight change, prior GLP-1 use, and major diagnoses. Third is the screening visit: labs, vitals, and whatever tests the protocol requires. You can pass one layer and still fail another.

If you want to be efficient, have your medication list, weight history, diagnoses, and recent lab information ready before contacting a site. Do not change medication or stop care just to fit a trial without your clinician involved.

What happens after you contact a study site?

The site may start with a short pre-screen. If you look like a possible match, the coordinator may schedule an informed-consent visit. Consent is where the team explains the study, risks, visits, placebo possibility, privacy rules, and your right to leave the study. You can ask questions before signing.

After consent, screening confirms whether you qualify. That can include weight, height, vital signs, labs, pregnancy testing when relevant, ECG, medication review, medical history, and sometimes imaging or disease-specific assessments. If you qualify, the study team assigns you according to the protocol.

Enrollment can mean frequent visits. It can mean a fixed dose schedule, symptom reporting, side-effect checks, and a long follow-up period. If a trial is randomized, you may not choose your arm. If it is blinded, you may not know which arm you are in while the study runs.

What study teams ask before clinical enrollment

A retatrutide clinical trial is usually built around obesity, weight loss, and safety. The study team may ask about your weight history, obesity diagnosis, current BMI, previous weight-loss attempts, and whether you have used another GLP-1 or incretin injection before. Prior GLP-1 use can matter because a clinical protocol may exclude recent treatment or require a washout period.

Expect questions about dose history, too. If you used a weight-loss injection before, the team may ask what dose you reached, whether the dose caused nausea or diarrhea, and whether you stopped because of side effects. That helps the clinical team judge whether trial participation is safe and whether your result would fit the study question.

Some obesity trials also ask about bariatric surgery or planned surgery. A recent surgery, a scheduled surgery, or weight-loss surgery history can change eligibility because it affects weight, appetite, labs, and the final result researchers are trying to measure. The best answer is not to guess. Tell the study team the full history and let the protocol decide.

The best trial candidate is not simply the person most eager to start. It is the person who fits the clinical criteria, can attend the study visits, understands that assignment may be randomized, and can follow the dose, injection, lab, and reporting schedule long enough for the trial result to mean something.

Trial access is different from provider-reviewed care

A clinical trial answers a research question. Provider-reviewed care answers a personal care question: what treatment is appropriate for you, with your history, goals, labs, medication list, and risk profile. Those are different paths.

If your goal is to help generate research data and you can meet the travel, time, and eligibility requirements, a trial may be worth exploring. If your goal is treatment outside a research protocol, a trial listing is not the right shortcut. You need a licensed provider to review your situation and decide what options fit.

That difference matters because it changes your expectations. A trial can help answer whether a medicine works for a population. A provider visit decides whether a treatment makes sense for one patient. Do not treat one as a shortcut for the other.

What if no retatrutide trial is recruiting near you?

That is common. A study can be active but not recruiting. It can be recruiting in some cities but not yours. A site can fill its slots. The listing can change before you contact anyone. If there is no practical trial option, the next step is not a peptide forum. It is a medical conversation about appropriate weight-loss care.

Use the trial record for research status and enrollment facts. Use the retatrutide overview for how the drug works, the retatrutide side effects guide for safety questions, and how to get retatrutide online for the provider-reviewed path. If price is the deciding factor, the retatrutide cost guide keeps cost, insurance, and availability separate from trial enrollment.

Side effects are part of trial screening

Retatrutide side effects matter before enrollment because a study team has to decide whether trial participation is safe for you. In the phase 2 trial, gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation were common and were generally tied to dose escalation.5 A trial may also monitor heart rate, labs, weight change, and symptoms on a fixed schedule. That monitoring is one reason the trial pathway has more rules than a normal online form.

If you already have side effects on another GLP-1 medication, take that seriously during screening. Bring your medication list and prior reaction history. The study team needs the full picture, and your own clinician should be involved if you are considering stopping, starting, or changing any medication.

Cost and insurance are different in a trial

Clinical trial cost is not the same question as the price of prescribed care. A research study may cover study medication, visits, or tests that are part of the protocol, but the details depend on the study and site. Ask the coordinator what is covered, what travel costs are your responsibility, and whether your insurance is billed for any routine care.

Do not compare a trial to a monthly retatrutide price as if they are the same product. Trial enrollment is research. You may not receive retatrutide, and you may not be eligible. Provider-reviewed care is a separate path with a clear price before payment. If cost, insurance, and month-to-month availability are your deciding factors, use the retatrutide cost guide instead of a trial listing.

What to confirm with the study coordinator

Before you try to enroll, confirm the practical details with the study coordinator. Ask whether the site is still screening new participants, whether your age and BMI fit the current criteria, whether prior incretin medication affects screening, and whether any current medication would need review before enrollment. A public listing can be current and still have a site that has filled its slots.

Confirm the visit schedule in plain terms. Some clinical studies require frequent visits early, then longer follow-up. Others require fasting labs, symptom diaries, weight checks, ECGs, or imaging. A trial can be scientifically appealing and still be impossible if the site is too far away or the appointment schedule conflicts with work, childcare, travel, or surgery plans.

Confirm what happens if side effects appear. The protocol may have rules for holding a dose, stepping down, reporting nausea, tracking hydration, or stopping the study drug. Those rules are part of clinical research. They protect the participant and the study result, but they also mean the study team, not the participant, controls the dose schedule.

Confirm what data you will receive and what stays blinded. In a blinded study, you may not know whether you received retatrutide, placebo, or another study arm while the trial is running. That can be frustrating if your main goal is immediate weight loss. It is also what makes the result scientifically useful.

Where Get Pep'd fits after the trial question

Get Pep'd is not a clinical trial site and does not enroll people into Lilly's TRIUMPH studies, which are listed through official clinical trial channels such as ClinicalTrials.gov and Lilly's trial finder.12 Get Pep'd uses licensed providers to review patients and determine whether weight-loss treatment is medically appropriate. If a provider prescribes, fulfillment follows the prescription path through a licensed US pharmacy.

If your practical question is whether to wait for a trial, stay on semaglutide, move from semaglutide to another option, or compare semaglutide with tirzepatide and retatrutide, that is a provider-review question rather than a trial sign-up question. Semaglutide and tirzepatide have different approval status, dosing, side-effect records, insurance patterns, and availability. A provider can help you decide whether current treatment still fits while retatrutide research continues.

Bottom line

Retatrutide trial sign up is a research process. Search the official listings, check recruiting status and locations, read the eligibility criteria, and contact the study site. Expect screening, visits, monitoring, and the possibility that you are not assigned to retatrutide. If a trial is not realistic for you, keep the paths separate: clinical trial enrollment is one route, provider-reviewed care is another.

This content is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA-approved for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Trial figures cited here are average results from the named clinical trials, not a promise of individual results. A licensed provider determines whether any treatment is appropriate for you. Results vary.